Medicine
Attruby 356 mg tablet
Attruby 356 mg tablet is a prescription medicine containing Acoramidis for oral use, marketed by BridgeBio Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store ATTRUBY at controlled room temperature 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Acoramidis
- Brand
- Attruby
- Strength
- 356 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 4 dose packs, 1 bottle
- Marketing authorisation holder
- BridgeBio Pharma
- Manufacturer
- BridgeBio Pharma
- Origin register
- US FDA, United States
- Storage
- Store ATTRUBY at controlled room temperature 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store in original blister card until use to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C01EB25 Acoramidis
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 November 2024
- Identifiers
- RxCUI 2698318, 2698324DailyMed set ID 913552ef-875d-4cb7-bf05-a7d20a394c38NDC 82228-712Application NDA216540
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 dose pack in 1 carton / 1 blister pack in 1 dose pack / 28 tablet, film coated in 1 blister pack | 82228-712-28 | BridgeBio Pharma | 22 November 2024 |
| 1 bottle in 1 carton / 120 tablet, film coated in 1 bottle | 82228-712-30 | BridgeBio Pharma | 18 June 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Acoramidis is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. It is available as tablets for oral use. MedsAcross supplies Acoramidis for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AcoramidisFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Attruby prescribing information (BridgeBio Pharma) · U.S. National Library of Medicine, DailyMed
- Beyonttra: European public assessment report (EPAR) · European Medicines Agency
Need Attruby 356 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.